Spear Bio has developed a groundbreaking immunoassay platform known as SPEAR technology, which is designed to provide ultra-sensitive protein insights from extremely small sample volumes. This innovative platform is capable of detecting trace biomarkers at the single-molecule level, significantly enhancing the sensitivity of biomarker assays. By utilizing a wash-free workflow, the SPEAR technology eliminates the need for high-affinity antibodies, allowing for a more streamlined and efficient process. The platform requires only 1 µL or less of sample volume, which is 100 times less than traditional immunoassays, making it particularly advantageous for applications where sample availability is limited.

The SPEAR technology employs a two-factor authentication mechanism to ensure that the signals detected originate from genuine proximity binding before amplification through standard quantitative PCR (qPCR). This approach effectively reduces non-specific transient noise, further enhancing the accuracy of biomarker detection. The versatility of the SPEAR platform allows for the broadening of ultra-sensitive biomarker assays across various diseases, including neurology, infectious diseases, and immunology, thereby facilitating advancements in biomarker research and development.

United States

Spear Bio, founded in 2021, is a well-funded and rapidly growing start-up headquartered in Woburn, Massachusetts.  Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar levels from sub-microliter sample volumes, enabling unprecedented sensitivity.   We are dedicated to revolutionizing early disease diagnosis and monitoring, empowering clinicians and researchers to improve patient outcomes, and advance global health.

For more information, please visit www.spear.bio or email info@spear.bio.

Spear Bio

Company Details